AR134635A1 - MOLÉCULA DE siRNA PARA INHIBIR LA EXPRESIÓN DE PCSK9 Y USO DE LA MISMA - Google Patents

MOLÉCULA DE siRNA PARA INHIBIR LA EXPRESIÓN DE PCSK9 Y USO DE LA MISMA

Info

Publication number
AR134635A1
AR134635A1 ARP240103412A ARP240103412A AR134635A1 AR 134635 A1 AR134635 A1 AR 134635A1 AR P240103412 A ARP240103412 A AR P240103412A AR P240103412 A ARP240103412 A AR P240103412A AR 134635 A1 AR134635 A1 AR 134635A1
Authority
AR
Argentina
Prior art keywords
pcsk9
products
sirna molecule
expression
sirna
Prior art date
Application number
ARP240103412A
Other languages
English (en)
Inventor
Rui Zhang
Dongdong Wang
Xinxing Liu
Rui Zhou
Qingqiao Tan
Original Assignee
Hangzhou Dinovate Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Dinovate Biotech Co Ltd filed Critical Hangzhou Dinovate Biotech Co Ltd
Publication of AR134635A1 publication Critical patent/AR134635A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al campo técnico de la terapia génica, y, específicamente, a una molécula de siRNA (small interference RNA, por sus siglas en inglés, ARN pequeño de interferencia) para inhibir la expresión de PCSK9 y al uso de la misma. Particularmente, se divulgan una molécula de siRNA para inhibir la expresión de PCSK9 (que comprende una hebra sentido y una hebra antisentido que son complementarias para formar una región de doble hebra) y una composición farmacéutica que comprende la misma. La molécula de siRNA tiene una alta eficiencia de silenciamiento y un efecto de silenciamiento de larga duración para el gen PCSK9 y es útil en la fabricación de productos para inhibir la expresión de la proteína PCSK9, productos para reducir la concentración de lipoproteínas de baja densidad o colesterol de lipoproteínas de baja densidad en suero; y productos para aliviar los síntomas de enfermedades mediadas por el gen PCSK9.
ARP240103412A 2023-12-11 2024-12-11 MOLÉCULA DE siRNA PARA INHIBIR LA EXPRESIÓN DE PCSK9 Y USO DE LA MISMA AR134635A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311686000.7A CN117384907B (zh) 2023-12-11 2023-12-11 抑制PCSK9表达的siRNA分子及其应用

Publications (1)

Publication Number Publication Date
AR134635A1 true AR134635A1 (es) 2026-02-04

Family

ID=89441337

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240103412A AR134635A1 (es) 2023-12-11 2024-12-11 MOLÉCULA DE siRNA PARA INHIBIR LA EXPRESIÓN DE PCSK9 Y USO DE LA MISMA

Country Status (4)

Country Link
CN (1) CN117384907B (es)
AR (1) AR134635A1 (es)
TW (1) TW202540421A (es)
WO (1) WO2025124364A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117384907B (zh) * 2023-12-11 2024-03-29 上海鼎新基因科技有限公司 抑制PCSK9表达的siRNA分子及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484588B (zh) * 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
US9187746B2 (en) * 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
IL292159B1 (en) * 2012-12-05 2026-04-01 Alnylam Pharmaceuticals Inc PCSK9 iRNA compositions and methods of using them
CN108348541A (zh) * 2015-08-25 2018-07-31 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
CN107400669A (zh) * 2016-08-18 2017-11-28 广州市锐博生物科技有限公司 用于抑制HIF1A靶基因mRNA表达的寡核酸分子及其成套组合物
JOP20190215A1 (ar) * 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
CN109957565B (zh) * 2017-12-26 2023-04-07 广州市锐博生物科技有限公司 一种修饰的siRNA分子及其应用
JP7357002B2 (ja) * 2018-04-18 2023-10-05 ディセルナ ファーマシューティカルズ インコーポレイテッド 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド
CN115066498A (zh) * 2020-03-16 2022-09-16 阿尔戈诺特Rna有限公司 Pcsk9的拮抗剂
WO2022079221A1 (en) * 2020-10-16 2022-04-21 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
CN114716518A (zh) * 2021-01-06 2022-07-08 圣诺制药公司 一种能够抑制pcsk9表达的分子构造及药物组合物
CN113234725B (zh) * 2021-05-28 2022-02-18 厦门甘宝利生物医药有限公司 一种抑制pcsk9基因表达的rna抑制剂及其应用
WO2023284763A1 (zh) * 2021-07-16 2023-01-19 苏州瑞博生物技术股份有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
US20250346902A1 (en) * 2022-01-13 2025-11-13 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Rnai agent inhibiting pcsk9 gene expression and application thereof
CN117186172A (zh) * 2023-07-19 2023-12-08 上海鼎新基因科技有限公司 缀合物基团、缀合物及其制备方法和应用
CN117384907B (zh) * 2023-12-11 2024-03-29 上海鼎新基因科技有限公司 抑制PCSK9表达的siRNA分子及其应用

Also Published As

Publication number Publication date
CN117384907A (zh) 2024-01-12
TW202540421A (zh) 2025-10-16
WO2025124364A1 (en) 2025-06-19
CN117384907B (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
CL2021002326A1 (es) Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso (divisional de solicitud n° 202002865)
MX2019005816A (es) Agentes de arn modificados con efecto reducido fuera de la diana.
MX2022013606A (es) Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
MX2023008469A (es) Oligonucleotidos de doble hebra modificados.
MX2022015149A (es) Composiciones de acido ribonucleico de interferencia (arni) de xantina dehidrogenasa (xdh) y metodos de uso de las mismas.
MX2023005696A (es) Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas.
AR121312A2 (es) AGENTES DE ARNi, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR)
CL2021001490A1 (es) Constructos de iarn modificados químicamente y usos de estos
AR134635A1 (es) MOLÉCULA DE siRNA PARA INHIBIR LA EXPRESIÓN DE PCSK9 Y USO DE LA MISMA
MX2024008022A (es) Composiciones y kits para el tratamiento de la hemofilia a o b.
AR117297A1 (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos
MX2024005652A (es) Agentes de acido ribonucleico (arn) de cadena doble modificados.
JP2009538626A (ja) 送達方法
BR112017021967A2 (pt) composições do fator xii (fator hageman) (f12), kallikrein b, plasma (fator fletcher) 1 (klkb1), e kininogen 1 (kng1) irna e métodos de uso dos mesmos
CL2024000341A1 (es) Composiciones de arni y métodos para silenciar el angiotensinógeno (agt)
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
PE20210921A1 (es) Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden
CO2023012562A2 (es) Composiciones de arni de cetohexocinasa (khk) y métodos de uso de las mismas
MX2022001767A (es) Construcciones de vesículas-oligonucleótidos antisentido (aso) extracelulares que se dirigen a transductor de señal y activador de la transcripción 6 (stat6).
EA201590070A1 (ru) ИНГИБИТОРЫ МИКРОРНК СЕМЕЙСТВА miR-15
MX2022015365A (es) Composiciones y métodos para el tratamiento del covid largo.
BR112017018329A2 (pt) composição para prevenir ou tratar calcificação de válvula, contendo inibidor de dpp-4
CO2024000475A2 (es) Oligonucleótidos antisentido pikfyve
Zhou et al. MicroRNA-9-3p aggravates cerebral ischemia/reperfusion injury by targeting fibroblast growth factor 19 (FGF19) to inactivate GSK-3β/Nrf2/ARE signaling
AR129710A1 (es) Composiciones y métodos para inhibir la expresión de serina proteasa transmembrana 6 (tmprss6)